Abstract
Purpose
This study tests the hypothesis that pegylated dendrimeric micelles prolong the half-life of low molecular weight heparin (LMWH) and increase the drug’s pulmonary absorption, thereby efficacious in preventing deep vein thrombosis (DVT) in a rodent model.
Materials and Methods
Pegylated PAMAM dendrimer was synthesized by conjugating G3 PAMAM dendrimer with methyl ester of polyethylene glycol 2000 (PEG-2000). Fourier transform infrared (FTIR), nuclear magnetic resonance (NMR) spectra and thin layer chromatography (TLC) were used to evaluate the identity and purity of pegylated dendrimer. The particle size distributions of the formulations were measured by using a Nicomp Zeta meter, and drug entrapment efficiency was studied by azure A assay. The efficacy of pegylated dendrimers in enhancing pulmonary absorption, prolonging drug half-life, and preventing DVT was studied in a rodent model.
Results
FTIR, NMR and TLC data confirmed that PAMAM dendrimer was conjugated to PEG-2000. The entrapment efficiency of LMWH in PEG–dendrimer micelles was about 40%. Upon encapsulation of LMWH, the particle size of PEG–dendrimer micelles increased from 11.7 to 17.1 nm. LMWH entrapped in PEG–dendrimer produced a significant increase in pulmonary absorption and the relative bioavailability of the formulation was 60.6% compared to subcutaneous LMWH. The half-life of the PEG–dendrimer-based formulation was 11.9 h, which is 2.4-fold greater than the half-life of LMWH in a saline control formulation. When the formulation was administered at 48-h intervals, the efficacy of LMWH encapsulated in pegylated dendrimers in reducing thrombus weight in a rodent model was very similar to that of subcutaneous LMWH administered at 24-h intervals.
Conclusions
Pegylated PAMAM dendrimer could potentially be used as a carrier for pulmonary delivery of LMWH for the long-term management of DVT.
Similar content being viewed by others
References
K. T. Al-Jamal, C. Ramaswamy, and A. T. Florence. Supramolecular structures from dendrons and dendrimers. Adv Drug Deliv Rev. 57:2238–2270 (2005). doi:10.1016/j.addr.2005.09.015.
A. D’Emanuele, and D. Attwood. Dendrimer–drug interactions. Adv Drug Deliv Rev. 57:2147–2162 (2005). doi:10.1016/j.addr.2005.09.012.
C. Dufes, I. F. Uchegbu, and A. G. Schatzlein. Dendrimers in gene delivery. Adv Drug Deliv Rev. 57:2177–2202 (2005). doi:10.1016/j.addr.2005.09.017.
R. Duncan, and L. Izzo. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev. 57:2215–2237 (2005). doi:10.1016/j.addr.2005.09.019.
A. T. Florence, and N. Hussain. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv Drug Deliv Rev. 50:S69–89 (2001). doi:10.1016/S0169-409X(01)00184-3.
K. M. Kitchens, M. E. El-Sayed, and H. Ghandehari. Transepithelial and endothelial transport of poly (amidoamine) dendrimers. Adv Drug Deliv Rev. 57:2163–2176 (2005). doi:10.1016/j.addr.2005.09.013.
H. Kobayashi, and M. W. Brechbiel. Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev. 57:2271–2286 (2005). doi:10.1016/j.addr.2005.09.016.
S. Svenson, and D. A. Tomalia. Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev. 57:2106–2129 (2005). doi:10.1016/j.addr.2005.09.018.
S. Bai, C. Thomas, A. Rawat, and F. Ahsan. Recent progress in dendrimer-based nanocarriers. Crit Rev Ther Drug Carrier Syst. 23:437–495 (2006).
J. C. Roberts, M. K. Bhalgat, and R. T. Zera. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J Biomed Mater Res. 30:53–65 (1996). doi:10.1002/(SICI)1097-4636(199601)30:1<53::AID-JBM8>3.0.CO;2-Q.
S. M. Moghimi, A. C. Hunter, and J. C. Murray. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 53:283–318 (2001).
Y. Qi, G. Zhao, D. Liu, Z. Shriver, M. Sundaram, S. Sengupta, G. Venkataraman, R. Langer, and R. Sasisekharan. Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route. Proc Natl Acad Sci U S A. 101:9867–9872 (2004). doi:10.1073/pnas.0402891101.
T. Yang, J.J. Arnold, and F. Ahsan. Tetradecylmaltoside (TDM) enhances in vitro and in vivo intestinal absorption of enoxaparin, a low molecular weight heparin. J Drug Target. 13:29–38 (2005). doi:10.1080/10611860400020191.
T. Yang, A. Hussain, S. Bai, I. A. Khalil, H. Harashima, and F. Ahsan. Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin. J Control Release. 115:289–297 (2006). doi:10.1016/j.jconrel.2006.08.015.
T. Yang, F. Mustafa, and F. Ahsan. Alkanoylsucroses in nasal delivery of low molecular weight heparins: in-vivo absorption and reversibility studies in rats. J Pharm Pharmacol. 56:53–60 (2004). doi:10.1211/0022357022377.
T. Yang, F. Mustafa, S. Bai, and F. Ahsan. Pulmonary delivery of low molecular weight heparins. Pharm Res. 21:2009–2016 (2004). doi:10.1023/B:PHAM.0000048191.69098.d6.
S. Bai, C. Thomas, and F. Ahsan. Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin. J Pharm Sci. 96:2090–2106 (2007). doi:10.1002/jps.20849.
H. Yang, J. J. Morris, and S. T. Lopina. Polyethylene glycol-polyamidoamine dendritic micelle as solubility enhancer and the effect of the length of polyethylene glycol arms on the solubility of pyrene in water. J Colloid Interface Sci. 273:148–154 (2004). doi:10.1016/j.jcis.2003.12.023.
C. Kojima, K. Kono, K. Maruyama, and T. Takagishi. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug Chem. 11:910–917 (2000). doi:10.1021/bc0000583.
D. Bhadra, S. Bhadra, S. Jain, and N. K. Jain. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm. 257:111–124 (2003). doi:10.1016/S0378-5173(03)00132-7.
K. Maruyama, T. Yuda, A. Okamoto, S. Kojima, A. Suginaka, and M. Iwatsuru. Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). Biochimica et Biophysica Acta. 1128:44–49 (1992).
D. A. Tomalia, A. M. Naylor, and W. A. Goddard III. Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter. Angew Chem, Int Ed Engl. 29:138–175 (1990). doi:10.1002/anie.199001381.
J. S. Choi, E. J. Lee, Y. H. Choi, Y. J. Jeong, and J. S. Park. Poly(ethylene glycol)-block-poly(L-lysine) dendrimer: novel linear polymer/dendrimer block copolymer forming a spherical water-soluble polyionic complex with DNA. Bioconjug Chem. 10:62–65 (1999). doi:10.1021/bc9800668.
R. Jevprasesphant, J. Penny, R. Jalal, D. Attwood, N. B. McKeown, and A. D’Emanuele. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm. 252:263–266 (2003). doi:10.1016/S0378-5173(02)00623-3.
M. Liu, K. Kono, and J. M. Frechet. Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. J Control Release. 65:121–131 (2000). doi:10.1016/S0168-3659(99)00245-X.
G. Pan, Y. Lemmouchi, E. O. Akala, and O. Bakare. Studies on PEGylated and drug-loaded PAMAM dendrimers. J Bioact Compat Polym. 20:113–128 (2005). doi:10.1177/0883911505049656.
Y. Haba, C. Kojima, A. Harada, T. Ura, H. Horinaka, and K. Kono. Preparation of poly(ethylene glycol)-modified poly(amido amine) dendrimers encapsulating gold nanoparticles and their heat-generating ability. Langmuir. 23:5243–5246 (2007). doi:10.1021/la0700826.
R. Q. Huang, Y. H. Qu, W. L. Ke, J. H. Zhu, Y. Y. Pei, and C. Jiang. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J. 21:1117–1125 (2007). doi:10.1096/fj.06-7380com.
T. Ooya, J. Lee, and K. Park. Effects of ethylene glycol-based graft, star-shaped, and dendritic polymers on solubilization and controlled release of paclitaxel. J Control Release. 93:121–127 (2003). doi:10.1016/j.jconrel.2003.07.001.
K. Salartash, M. D. Gonze, A. Leone-Bay, R. Baughman, W. C. Sternbergh 3rd, and S. R. Money. Oral low-molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat. J Vasc Surg. 30:526–531 (1999). doi:10.1016/S0741-5214(99)70080-7.
M. D. Gonze, K. Salartash, W. C. Sternbergh 3rd, R. A. Baughman, A. Leone-Bay, and S. R. Money. Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation. 101:2658–2661 (2000).
Acknowledgement
This study was supported by NIH R15 HL7713302.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bai, S., Ahsan, F. Synthesis and Evaluation of Pegylated Dendrimeric Nanocarrier for Pulmonary Delivery of Low Molecular Weight Heparin. Pharm Res 26, 539–548 (2009). https://doi.org/10.1007/s11095-008-9769-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-008-9769-y